Fulgent Genetics: Raised Forecast and Strong Study Results Drive Stock to 12-Month High
Reading Time: 3 minutes
After a record revenue of 32.5 million USD in 2019, Fulgent sharply boosted its revenues during the COVID-19 years of 2020 and 2021 to 422 million USD and 993 million USD, respectively. At the same time, the stock reached its current all-time high in early 2021. The rapid decline in demand for COVID-19 tests subsequently led to a drop in both revenue and stock price. After only a slight decline in revenue in 2024, Fulgent is now back on track for its first growth since 2021 after three quarters in 2025. The announcement of the latest quarterly figures...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
